Curiously, whole-exome sequencing and methylation profiling in a cohort of CLL patients before venetoclax treatment and at the time of venetoclax resistance revealed no genetic alterations in BCL2 [30]. This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.